Safety of USCIT-MPL-4: Prevalence and Risk Factors of Systemic Reactions in Real Life

• DOI: 10.2217/imt-2019-0009
• Publication Date: 2019-05-16T10:12:41Z
• Authors: Marco Caminati; Alessandra Arcolaci; Massimo Guerriero; Giuseppina Manzotti; Mariangiola Crive...; Giovanni Rolla; Filippo Fassio; Gianenrico Senna
• Keywords: Adult; Male; Adolescent; Rhinitis, Allergic, Seasonal; Middle Aged; adjuvants; allergic asthma; allergic rhinitis; immunotherapy; local reactions; risk factors; safety; subcutaneous immunotherapy; systemic reaction grading system; systemic reactions; Asthma; 3. Good health; Young Adult; 03 medical and health sciences; Lipid A; Treatment Outcome; 0302 clinical medicine; Adjuvants, Immunologic; Italy; Risk Factors; Child, Preschool; Hypersensitivity; Prevalence; Humans; Female; Prospective Studies; Child; Aged

Aim: We assessed the safety of allergoid adjuvanted by monophosphoryl lipid A (uSCIT-MPL-4) in a real-life setting. Materials & methods: Patients treated with uSCIT-MPL-4 were followed-up for 1 year. Systemic reactions (SRs) were registered and the association with potential risk factors was evaluated. Results: 2929 patients were included. Grade 0, 1, 2, 3 and 4 SR reactions were observed respectively in 3.3, 1.5, 0.31, 0.07 and 0.07% of patients. A significant association was detected between Grade ≥1 SRs and: female gender, number of administrations, previous local reactions. Conclusion: uSCIT-MPL-4 is safe. Local reactions should be accurately assessed as they may represent a risk factor for Grade ≥1 SRs, together with gender and number of doses/year.